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Background: To evaluate the specific growth rate (SGR) of ameloblastoma. 
Material and Methods: cases of ameloblastoma initially underdiagnosed (e.g. cases overlooked or diagnosed as re-
active lesions) which had adequate radiographic documentation to evaluate their progression were retrospectively 
selected. Two panoramic radiographs were analyzed to determine the specific growth rate (SGR) of each tumor, 
defined as the logarithm of the ratio of final tumor area (when the diagnosis of ameloblastoma was made) to the 
initial tumor area (when the lesion was underdiagnosed), divided by the time interval between the radiographic 
images. The tumor area was measured using the software ImageJ. 
Results: Twelve patients with mandibular ameloblastomas were selected, including 5 males and 7 females, with a 
mean age of 24.9 years (range: 14-61 years). In four cases, the lesion was associated with the crown of an impacted 
third molar. In three cases, it was initially diagnosed as a periapical lesion. Three cases were extrafollicular and 
were not noticed in the initial radiographs. Two cases were initially diagnosed as ameloblastoma, but the surgery 
was delayed for personal reasons. The mean interval of time between the two radiographic images was 4.3 years 
(range: 0.4-9 years). Based on our analysis, ameloblastoma grows in average 40.4% per year (range: 14.9-88.7%). 
Conclusions: Ameloblastoma is a progressively growing tumor, but its growth rate seems to be smaller than 
initially reported in the literature. Better understanding the radiographic progression of ameloblastoma might 
improve its early diagnosis, management, and prognosis.
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Introduction
Ameloblastoma is the most common odontogenic tumor, 
which is characterized by progressive growth, bone ex-
pansion and local recurrence (1-3). Ameloblastoma usu-
ally occurs as unilocular or multilocular radiolucencies 
in the posterior region of the mandible of adults, with no 
sex predilection and a wide age range (3,4).
Clinically, asymptomatic swelling in the involved area 
is the main complaint, but lesions may be occasionally 
painful (5,6). Besides, duration of symptoms until diag-
nosis varies considerably (3), and patients’ perception 
of symptoms might not represent the natural history of 
ameloblastoma (6).
Currently, there is limited data in the literature explor-
ing the growth rate and time of progression of amelo-
blastoma (6-8). Therefore, we aimed to estimate the 
growth of ameloblastoma based on its early radiograph-
ic manifestations. 
Material and Methods
Cases of ameloblastoma were retrospectively selected 
from the files of Clinics Hospital of the Medical School 
of the University of São Paulo (USP) São Paulo, Bra-
zil, Federal University of Rio de Janeiro (UFRJ) Rio de 
Janeiro-Brazil, and Piracicaba Dental School, Univer-
sity of Campinas (UNICAMP), São Paulo, Brazil in the 
period from 1999 to 2018. 
-Inclusion criteria 
To evaluate ameloblastoma progression, cases with at 
least two panoramic images – one immediately prior 
to the diagnosis (final) and another panoramic radio-
graph where the lesion already could be seen, but it was 
initially underdiagnosed (initial). In the initial radio-
graphs, the lesions were either overlooked, or diagnosed 
as periapical lesions, dentigerous cysts, or enlarged den-
tal follicles. 
-Exclusion criteria
Cases with incomplete clinical data, insufficient radio-
graphic documentation or previous surgery were ex-
cluded from this study.
Specific radiographic growth rate assessment 
The tumor area in both radiographic images of each case 
included in the study was measured by software ImageJ 
(version 1.51j8, National Institutes of Health, USA) (9). 
For each case, the mesial-distal distance of a molar ad-
jacent to the lesion was measured in both radiograph 
images using the “straight line” tool. This distance was 
used to calibrate the measurement tool. The “polygon 
selection” tool was then used to calculate the virtual 
area (initial and final) of the lesions. To determine the 
specific growth rate (SGR; growth % per year) of am-
eloblastoma, the formula described by Mehrara et al. 
(10) to quantify tumor response to antineoplastic treat-
ment was adapted to our study. Hence, the logarithm 
of the ratio of final tumor area (A2) to the initial tumor 
area (A1) was divided by the time interval between the 
radiographic images (T2 - T1), as follows: SGR = ln(A2/
A1)/T2 – T1.
Consequently, an estimated growth percentage per year 
was calculated for patients with ameloblastoma. This 
study was approved by the local Institutional Ethics 
Committee, under the protocol 03586418.4.0000.5418, 
following the Helsinki Declaration for studies involving 
human subjects.
Results
Twelve cases fulfilled our inclusion criteria. There were 
5 males and 7 females, with a mean age of 24.9 years 
(range: 14-61 years). All tumors occurred in the mandi-
ble, eleven of them in the posterior region, with a single 
case affecting the anterior region. The mean interval 
of time between the two radiographic images was 4.3 
years (range: 0.42-9 years). Based on our analysis, mean 
SGR was 40.4% per year (range: 14.9-88.7%), as showed 
in Table 1. In four cases (5, 6, 8, and 11), the ameloblas-
toma was associated with the crown of an unerupted 
third molar, and in three cases (2, 9, and 12), the tumor 
was misdiagnosed at first as a periapical lesion.   Three 
cases (1, 3, and 4) were extrafollicular, and were not 
noticed in the initial radiographs. Cases 7 and 10 were 
initially diagnosed as ameloblastoma, but the surgery 
was delayed for personal reasons. Eleven cases were 
microscopically diagnosed as multicystic ameloblasto-
mas, and one case (case 9) as unicystic ameloblastoma.
Representative images of four of the cases are pre-
sented below (Figs. 1,2). In case 9, a 14-year-old male 
presented a well-defined radiolucency causing root re-
sorption of the right lower first molar noticed during 
evaluation of a panoramic radiograph acquired during 
orthodontic treatment. The panoramic radiograph ac-
quired 2.5 years earlier showed a smaller radiolucency 
between the right lower second premolar and first molar 
(Fig. 1A-B). In case 2, a 15-year-old female presented 
a small well-defined radiolucency associated with the 
right lower second molar. After 5 years, the tooth had 
been endodontically treated, but the lesion significantly 
progressed, displacing distally the third molar and infe-
riorly the mandibular canal (Fig. 1C-D).
In case 6, a 19-year-old female was diagnosed with an 
expansile ameloblastoma in the left ramus of the man-
dible causing displacement of the third molar and the 
mandibular canal. The patient had another panoramic 
radiograph taken 6 years prior to the diagnosis, where 
small radiolucencies were observed around the crown 
of both lower third molars, compatible with enlarged 
dental follicles/dentigerous cysts. Evaluating the cur-
rent radiograph, the right third molar erupted normally, 
while the tumor developed in the opposite site (Fig. 2A-
B). In case 4, an 18-year-old female presented a small, 
round and unilocular radiolucency located distally to 
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Fig. 1: Progression of Ameloblastoma seen in cases 9 (A-B) and 2 
(C-D). (A) a radiolucent image is seen associated with the mesial root 
of the right inferior first molar. (B) After 2.5 years of orthodontic 
treatment, the lesion increased in size, causing root displacement and 
resorption. (C) A small radiolucent image is seen associated with the 
right inferior second molar. (D) After 5 years, the tooth was end-
odontically treated, but the lesion significantly progressed, distally 
displacing the third molar.




1 14 M Right body U U Multicystic 7 31.4%
2 15 F Right body U Mt Multicystic 5 46.2%
3 19 M Left body U Mt Multicystic 2 77.9%
4 18 F Left ramus U Mt Multicystic 8 32.1%
5 23 F Left body U Mt Multicystic 2 22.3%
6 19 F Left ramus U Mt Multicystic 6 35.0%
7 61 F Anterior Mt Mt Multicystic 0.8 40.4%
8 15 M Right ramus Mt Mt Multicystic 0.4 88.7%
9 14 F Right body U U Unicystic 2.5 55.8%
10 47 M Left body U Mt Multicystic 1.7 20.4%
11 23 F Left ramus U Mt Multicystic 9 20.1%
12 31 M Right body U Mt Multicystic 8 14.9%
Table 1: Clinical features and specific growth rate (SGR) of 12 cases of ameloblastoma.
F: female, M: male, U: unilocular, Mt: multilocular SGR: specific growth rate.
Fig. 2: Progression of Ameloblastoma seen in cases 6 (A-B) and 4 (C-
D). (A) Small radiolucent images are seen around the inferior third 
molars. (B) Note the normal eruption of the right inferior third molar, 
while a radiolucent image occupies the left ramus after 6 years. (C) 
A small round radiolucent image is seen distally to the left inferior 
second molar. (D) After 8 years, the lesion increased significantly, 
occupying part of ramus and body of the mandible.
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the left inferior second molar, replacing the third mo-
lar, which is absent. After 8 years, the lesion increased 
significantly, assumed a multilocular aspect, expanding 
the bone cortices of the posterior mandible and causing 
root resorption of the second molar (Fig. 2 C,D).
Discussion
Ameloblastoma is a progressively growing benign odon-
togenic tumor characterized by its aggressive behavior 
and local recurrence (1). Nearly 90% of ameloblastomas 
present mutations in genes related to the MAPK path-
way (11), specifically the BRAF V600E, which has di-
agnostic and prognostic implications (12,13).
However, few studies have quantified ameloblastoma 
growth rate (6-8). Odukoya & Effiom (7) analyzed one 
hundred cases of ameloblastoma and correlated the 
estimated volume of the tumor with the duration of 
symptoms, estimating a growth rate of 0.81cm3/month 
(9.72 cm3/year) for conventional ameloblastoma, and 
of 0.17cm3/month (2.04 cm3/year) for unicystic amelo-
blastoma. Similarly, Effiom & Odukoya (8) evaluated 
the largest diameter of ameloblastomas and compared 
it with the duration of the tumor (in months). Thereby, 
the authors estimated that conventional ameloblastomas 
grew an average of 0.7 cm/month. Despite these stud-
ies had added valuable information to better understand 
the clinical progression of ameloblastoma, they used 
the duration of symptoms reported by patients during 
consultation to calculate the tumors’ growth rate, which 
may not represent an accurate measure of time. 
Interestingly, Chae et al. (6) attempted to establish the 
SGR of ameloblastoma in a systematic review with me-
ta-analysis, estimating a mean SGR of 87.8% per year. 
The authors searched the literature for case reports or 
case series of ameloblastoma where all three dimen-
sions and the duration of symptoms of the tumor were 
reported. Sixteen studies were selected, including 14 
reports of single cases and 2 case series (14-25). How-
ever, these studies do not have a previous documenta-
tion of any case. Once more, the time period used in all 
analyses is based on patients’ perception of symptoms, 
which may not be completely exact. Furthermore, since 
the authors did not have an initial measure to calculate 
the SGR of the tumors, they simply divided the final 
measure by 1, which could further distort this analysis.
In addition, Pereira-Castro-Lopes et al. (26) reported a 
case of a 20-year-old male presenting a significant am-
eloblastoma lesion occupying the right body and ramus 
of the mandible, causing tooth resorption. The patient 
had another radiograph taken 4 years before for orth-
odontic planning purposes. A circumscribed unilocular 
image could already be observed in association with 
an unerupted third molar. Applying the same formula 
used in our study, an SGR of 29.5%/year was calculated, 
which is in accordance with our results.
We found a smaller SGR (40.4%/year) compared to 
the study of Chae et al. (6) (87.8%/year), which might 
be explained by a delayed perception of symptoms by 
patients, since the lesion could be present long before 
the first symptom, thereby inflating the SGR calculat-
ed. The highest SGR values (88.7% and 77.9% growth 
per year) in our series occurred in young males (15 and 
19-year-old, respectively) with small intervals of time 
between radiographs (0.42 and 2 years, respectively), 
which could indicate that ameloblastoma may exhibit 
an accelerated growth in determined periods of time.
Remarkably, three of our cases were initially diagnosed 
as periapical lesions, reinforcing that careful evaluation 
of clinical, radiographic and microscopic features is im-
perative to diagnose ameloblastoma, avoiding unneces-
sary endodontic treatment, therefore delaying proper 
management (27). Furthermore, another two cases were 
initially considered as dentigerous cysts or enlarged 
dental follicles. Hence, it seems reasonable to maintain 
close follow-up for lesions that might rise suspicion of 
ameloblastoma, and a biopsy must be performed to sta-
blish a definite diagnosis.
We acknowledge the fact that panoramic radiographs 
depict a bidimensional representation of the real tumor, 
and these images are subjected to distortion, which 
may not reflect the real size of a lesion (28). Moreover, 
computed tomography (CT) and magnetic resonance 
imaging (MRI) analyses would not only contribute to 
evaluate ameloblastoma progression, but also aid in dis-
tinguishing ameloblastomas from other cyst like lesions 
(29,30). However, considering the lack of solid evidence 
in the literature, we believe that the analysis performed, 
despite simple, might improve the current understand-
ing about ameloblastoma natural progression when not 
treated. 
In summary, we estimate that ameloblastoma has a 
mean growth rate of 40.4% per year, which represents a 
considerably smaller percentage than previous reported 
in the literature. Better understanding the radiographic 
progression of ameloblastoma might improve its early 
diagnosis, management, and prognosis. 
References
1. El-Naggar AK, Chan JKC, Grandis JR, Takata TSPJ, ed. WHO 
Classification of Head and Neck Tumours. 4th ed. Lyon: IARC; 2017.
2. Hertog D, van der Waal I. Ameloblastoma of the jaws: A critical 
reappraisal based on a 40-years single institution experience. Oral 
Oncol. 2010;46:61-64. 
3. Reichart PA, Philipsen HP, Sonner S. Ameloblastoma: Biological 
profile of 3677 cases. Eur J Cancer Part B Oral Oncol. 1995;31:86-99. 
4. Dhanuthai K, Chantarangsu S, Rojanawatsirivej S, et al. Amelo-
blastoma: a multicentric study. Oral Surg Oral Med Oral Pathol Oral 
Radiol. 2012;113:782-788. 
5. Milman T, Ying G-S, Pan W, LiVolsi V. Ameloblastoma: 25 Year 
Experience at a Single Institution. Head Neck Pathol. 2016;10:513-
520.
6. Chae MP, Smoll NR, Hunter-Smith DJ, Rozen WM. Establishing 
the Natural History and Growth Rate of Ameloblastoma with Im-
plications for Management: Systematic Review and Meta-Analysis. 
Med Oral Patol Oral Cir Bucal. 2019 Jul 1;24 (4):e468-72.                                                                                                                                                                      Growth rate of ameloblastoma
e472
Elsalanty M, ed. PLoS One. 2015;10:e0117241. 
7. Odukoya O, Effiom OA. Clinicopathological study of 100 Nigerian 
cases of ameloblastoma. Niger Postgrad Med J. 2008;15:1-5.  
8. Effiom OA, Odukoya O. Desmoplastic ameloblastoma: analysis of 
17 Nigerian cases. Oral Surgery, Oral Med Oral Pathol Oral Radiol 
Endodontology. 2011;111:e27-e31. 
9. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 
25 years of image analysis. Nat Methods. 2012;9:671-675. 
10. Mehrara E, Forssell-Aronsson E, Bernhardt P. Objective assess-
ment of tumour response to therapy based on tumour growth kinet-
ics. Br J Cancer. 2011;105:682-686. 
11. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim 
MS, et al. Activating FGFR2-RAS-BRAF Mutations in Ameloblas-
toma. Clin Cancer Res. 2014;20:5517-5526.
12. Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kel-
lokoski J, et al. High frequency of BRAFV600E mutations in amelo-
blastoma. J Pathol. 2014;232:492-498. 
13. Diniz MG, Gomes CC, Guimarães BV, Castro WH, Lacerda JC, 
Cardoso SV, et al. Assessment of BRAFV600E and SMOF412E mu-
tations in epithelial odontogenic tumours. Tumor Biol. 2015;36:5649-
5653. 
14. Hunasgi S, Koneru A, Chauhan DS, Guruprasad Y. Rare Giant 
Granular Cell Ameloblastoma: A Case Report and an Immunohisto-
chemical Study. Case Rep Dent. 2013;2013:1-5. 
15. Catherine Z, Isaac S, Cotton F, Roch J, Rousset M, Bouletreau P, 
et al. Améloblastome géant mandibulaire. Rev Stomatol Chir Maxil-
lofac Chir Orale. 2013;114:97-101. 
16. Mijiti A, Ling W, Maimaiti A, Moming A. Single-stage manage-
ment of huge desmoplastic ameloblastoma of the anterior mandible. 
J Plast Reconstr Aesthetic Surg. 2013;66:1440-1441. 
17. Ota Y, Aoki T, Otsuru M, Hirabayashi K, Nakamura N, Tsuki-
noki K. Huge Ameloblastoma Associated With Hypercalcemia, Leu-
kocytosis, and Elevated Tumor Markers via Production of Parathy-
roid Hormone-Related Protein and Granulocyte Colony-Stimulating 
Factor. J Oral Maxillofac Surg. 2012;70:1380-1385. 
18. Chauhan DS, Guruprasad Y. Plexiform ameloblastoma of the 
mandible. J Clin Imaging Sci. 2011;1:61. 
19. Acharya S, Joshi A, Tayaar A, Gopalkrishnan K. Extreme amelo-
blastoma of the mandible with hypoproteinemia. A case report and 
review of clinicopathological features. J Clin Exp Dent. 2011;3:e343-
e347. 
20. Hata H, Ebihara M, Onitsuka T, Nakagawa M, Kitagawa Y, Ota 
Y. Large ameloblastoma of the mandible with hypoproteinemia. Int J 
Oral Maxillofac Surg. 2008;37:866-869. 
21. Mukhopadhyay S, Raha K, Mondal SC. Huge ameloblas-
toma of jaw-A case report. Indian J Otolaryngol Head Neck Surg. 
2005;57:247-248.  
22. Hughes CA, Wilson WR, Olding M. Giant ameloblastoma: re-
port of an extreme case and a description of its treatment. Ear Nose 
Throat J. 1999;78:568, 570-572, 574. 
23. Dunn JL, Olan WJ, Bank WO, Narang AK, Schwartz AM. Giant 
ameloblastoma: radiologic diagnosis and treatment. Radiographics. 
1997;17:531-536. 
24. Gordy FM, Holder R, Carroll MKO, Krolls SO. Growth of an am-
eloblastoma during pregnancy: Opportunity lost? Spec Care Dent. 
1996;16:199-203. 
25. Ueyama Y, Tsukamoto G, Matsumura T. Gigantic ameloblastoma 
of the mandible complicating hypoproteinemia: case report. J Cra-
niomaxillofac Surg. 1995;23:47-49. 
26. Pereira de Castro Lopes SL, Flores IL, de Oliveira Gamba T, et 
al. Aggressive unicystic ameloblastoma affecting the posterior man-
dible: late diagnosis during orthodontic treatment. J Korean Assoc 
Oral Maxillofac Surg. 2017;43:115. 
27. Gondak RO, Rocha AC, Neves Campos JG, et al. Unicystic Ame-
loblastoma Mimicking Apical Periodontitis: A Case Series. J Endod. 
2013;39:145-148. 
28. Devlin H, Yuan J. Object position and image magnification in 
dental panoramic radiography: a theoretical analysis. Dentomaxil-
lofacial Radiol. 2013;42:29951683-29951683. 
29. Apajalahti S, Kelppe J, Kontio R, Hagström J. Imaging character-
istics of ameloblastomas and diagnostic value of computed tomogra-
phy and magnetic resonance imaging in a series of 26 patients. Oral 
Surg Oral Med Oral Pathol Oral Radiol. 2015;120:e118-e130. 
30. Alves DBM, Tuji FM, Alves FA, Rocha AC, Santos-Silva ARD, 
Vargas PA, et al. Evaluation of mandibular odontogenic keratocyst 
and ameloblastoma by panoramic radiograph and computed tomog-
raphy. Dentomaxillofacial Radiol. 2018;47:20170288.
Acknowledgement
This work was supported in part by the Coordenação de Aperfeiçoa-
mento de Pessoal de Nível Superior – Brasil (CAPES) – Finance 
Code 001.
Conflict of interests
The authors declare no conflicts of interest.
